531 related articles for article (PubMed ID: 27645694)
21. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
[TBL] [Abstract][Full Text] [Related]
22. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
24. Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET.
Sobic Saranovic DP; Nikitovic M; Saponjski J; Grozdic Milojevic I; Paripovic L; Saranovic D; Beatovic S; Artiko VM
Eur J Radiol; 2020 Aug; 129():109076. PubMed ID: 32446127
[TBL] [Abstract][Full Text] [Related]
25. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
26. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy.
Xiang ZL; Erasmus J; Komaki R; Cox JD; Chang JY
Radiat Oncol; 2012 Aug; 7():144. PubMed ID: 22929048
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
Bailly C; Leforestier R; Campion L; Thebaud E; Moreau A; Kraeber-Bodere F; Carlier T; Bodet-Milin C
PLoS One; 2017; 12(8):e0183841. PubMed ID: 28841702
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study.
Im HJ; Zhang Y; Wu H; Wu J; Daw NC; Navid F; Shulkin BL; Cho SY
Radiology; 2018 Apr; 287(1):303-312. PubMed ID: 29357275
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
[TBL] [Abstract][Full Text] [Related]
30. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
31. Management and Outcome of Ewing Sarcoma of the Head and Neck.
Grevener K; Haveman LM; Ranft A; van den Berg H; Jung S; Ladenstein R; Klco-Brosius S; Juergens H; Merks JH; Dirksen U
Pediatr Blood Cancer; 2016 Apr; 63(4):604-10. PubMed ID: 26702872
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
Sato J; Yanagawa T; Dobashi Y; Yamaji T; Takagishi K; Watanabe H
Clin Exp Metastasis; 2008; 25(4):427-35. PubMed ID: 18301993
[TBL] [Abstract][Full Text] [Related]
33. Improved Outcome in Local Ewing Sarcoma With an Intensified Pilot Treatment Protocol SCMCIE 94.
Ash S; Yaniv I; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Avigad S; Cohen IJ
J Pediatr Hematol Oncol; 2019 Mar; 41(2):105-111. PubMed ID: 30570510
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.
Cuenca X; Hennequin C; Hindié E; Rivera S; Vercellino L; Baruch-Hennequin V; Gornet JM; Cattan P; Chirica M; Quéro L
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):477-85. PubMed ID: 23371374
[TBL] [Abstract][Full Text] [Related]
35. The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature.
Tal AL; Doshi H; Parkar F; Abraham T; Love C; Ye K; Yang R; Hoang B; Loeb D; Chou A; Geller D; Moadel R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):52-58. PubMed ID: 32815877
[TBL] [Abstract][Full Text] [Related]
36.
Bosma SE; Vriens D; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Bloem JL
Skeletal Radiol; 2019 Nov; 48(11):1735-1746. PubMed ID: 31016339
[TBL] [Abstract][Full Text] [Related]
37. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
38. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
[TBL] [Abstract][Full Text] [Related]
39. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
